KNOXVILLE, Tenn., Aug. 21, 2025 /PRNewswire/ — RADPAIR, the company specializing in generative AI-driven radiology reporting, today announced a new strategic partnership with AdvaHealth Solutions, a leading cloud-native PACS provider with a strong presence across Asia. This collaboration…
Radiology
OneMedNet initiates new Subscription Revenue model in partnership with Circle CVI
MINNEAPOLIS, Aug. 18, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced a long-term strategic partnership with Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in advanced cardiovascular imaging solutions. The collaboration reflects Circle CVI’s commitment to leveraging trusted, high-quality data to drive innovation in cardiac diagnostics, treatment planning, and AI model development with data being delivered in the next 30 days. Circle CVI selected OneMedNet’s iRWD™ platform to access diverse and regulatory-grade imaging, ECG, and other cardiovascular datasets that align with the stringent requirements of healthcare AI innovation. By partnering with OneMedNet, Circle CVI gains secure, de-identified access to a growing network of real-world cardiovascular imaging data from over 1,750 provider sites — spanning over 131 million exams critical to developing, validating, and improving advanced cardiovascular solutions. “Our initial experience with OneMedNet was exceptional — the quality, depth, and regulatory readiness of the data exceeded our expectations. It quickly became clear that this wasn’t just a one-time transaction, but the beginning of a long-term collaboration. That’s why we made the decision to partner with OneMedNet and move forward with a subscription — so we can continually access the high-quality, Real-World imaging data we trust to power our innovation,” said Erkan Akyuz, CEO of Circle CVI. This strategic collaboration enables Circle CVI to expand its research and development capabilities while ensuring alignment with evolving regulatory and clinical evidence standards. It also exemplifies a growing industry shift toward real-world evidence as a foundation for medical innovation. “We’re thrilled to enter into this long-term, collaborative relationship with Circle CVI,” said Aaron Green, President and CEO of OneMedNet. “This partnership is a testament to the quality of our Real-World Data — trusted by leading healthcare companies to accelerate innovation, by meeting the precise customer requirements for longitudinal clinical data with the ultimate goal of improving patient outcomes.” About OneMedNet Corporation OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,750 healthcare sites through its iRWD™ platform. This isn’t just data — it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption. Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities — rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com. About Circle Cardiovascular Imaging Circle Cardiovascular Imaging (Circle CVI) is a Canadian-based company that was founded in 2007, established with the aim of developing innovative software solutions to enhance cardiovascular and cerebrovascular imaging analysis and improve patient care. Circle CVI’s imaging platform provides best-in-class image reading and reporting for quantitative and qualitative assessment of cardiac MR, cardiac CT, vascular CT, and neuro CT. At the heart of Circle CVI’s operations is a relentless commitment to providing improved solutions for healthcare providers, ultimately driving better healthcare outcomes. This commitment fuels the company’s creativity, guides its decision making, and underpins its passion for innovation. Annually, millions of medical imaging exams — in over 1700 hospitals and in more than 90 countries — are estimated to be interpreted using cvi42. For additional information, please visit www.circlecvi.com or contact: marketing@circlecvi.com Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. We base these forward-looking statements on our current expectations and projections about future events, which we derive from the information presently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations. OneMedNet Contacts: Michael Wong, VP Marketing Email: michael.wong@onemednet.com SOURCE: ONEMEDNET CORPORATION
Philips Announces Plan for More Than USD 150 Million of New Investment in Manufacturing and R&D in the U.S. to Expand Production of AI-powered Health Technology Innovations
Global health technology leader, which serves 90% of U.S. hospitals, builds on top of existing U.S. investments to support local manufacturing and more than USD 900 million of annual R&D investment in the U.S. Philips EPIQ Elite Ultrasound CAMBRIDGE, Mass.–(BUSINESS WIRE)–Philips, a global leader in health technology, today announced a plan […]
Positron Corporation Secures Multi-Unit Sale of PET-CT Scanners to Leading Cardiology Group
Niagara Falls, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced the sale of four (4) PET-CT 64-slice scanners to a nationally recognized nuclear cardiology group specializing in advanced cardiovascular diagnostics and interventional care.
New Study Demonstrates Superiority of EggNest™ Complete Radiation Protection System in Comprehensive Protection for the Entire Interventional Team
MINNEAPOLIS, Aug. 13, 2025 /PRNewswire/ — A recent study published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlights the effectiveness of the EggNest™ Complete radiation shielding system, demonstrating its superior ability to protect all…
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of […]
Remedy Logic and RADIN Health® Execute Partnership Agreement
NEW YORK, July 21, 2025 /PRNewswire/ — Remedy Logic, a pioneer in radiology artificial intelligence, today announced it has signed a partnership agreement with RADIN Health® a leading cloud-based, all-in-one, RIS, PACS, Dictation AI®, and Select® workflow management solution, further…
Piccolo Medical, Inc. Receives FDA Clearance for 2nd Generation SmartPICC® technology
SAN FRANCISCO, July 16, 2025 /PRNewswire/ — Piccolo Medical, Inc. (Piccolo), a leading innovator in vascular access technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its next-generation SmartPICC® Stylet and PM2+™…
Sirtex Medical’s SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma
Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, Mass., July 7, 2025 /PRNewswire/ — Sirtex Medical (“Sirtex”), a leading manufacturer of…
UFE Doesn’t Remove Fibroids–Here’s What Women Aren’t Being Told
WASHINGTON, June 25, 2025 /PRNewswire/ — Every year, thousands of women are steered toward a fibroid treatment that doesn’t actually remove fibroids. Uterine Fibroid Embolization (UFE) may sound minimally invasive but it doesn’t remove fibroids; it just shrinks them, slightly, often with…